[
Bamford A., P. Kelleher, H. Lyall, M. Haston, M. Zancolli, D. Goldblatt and B. Kampmann. 2014. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. AIDS 28: 2033–2243.10.1097/QAD.0000000000000385416601425222526
]Search in Google Scholar
[
Centers for Disease Control and Prevention (CDC). 2013. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6–18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly. Rep. 62: 521–524.
]Search in Google Scholar
[
Concepcion N.F. and C.E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8: 266–272.10.1128/CDLI.8.2.266-272.20019604711238206
]Search in Google Scholar
[
Frenck R.Jr., A. Thompson, S. Senders, L. Harris-Ford, M. Sperling, S. Patterson, C. Devlin, K.U. Jansen, W.C. Gruber, E.A. Emini and others. 2014. 13-Valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or naïve to 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 33: 183–189.10.1097/INF.000000000000005624136369
]Search in Google Scholar
[
Levine A., S. Koletzko, D. Turner, J.C. Escher, S. Cucchiara, L. de Ridder, K.L. Kolho, G. Veres, R.K. Russell, A. Paerregaard and others. 2014. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J. Pediatr. Gastroenterol. Nutr. 58: 795–806.10.1097/MPG.000000000000023924231644
]Search in Google Scholar
[
Rubin L.G., M.J. Levin, P. Ljungman, E.G. Davies, R. Avery, M. Tomblyn, A. Bousvaros, S. Dhanireddy, L. Sung, H. Keyserling and others. 2014. Infectious diseases society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin. Infect. Dis. 58:309–318.
]Search in Google Scholar
[
Skoczyńska A., A. Kuch, E. Sadowy, I. Waśko, M. Markowska, P. Ronkiewicz, B. Matynia, A. Bojarska, K. Wasiak, A. Gołębiewska and others. 2015. Participants of a laboratory-based surveillance of community acquired invasive bacterial infections (BINet). Recent trends in epidemiology of invasive pneumococcal disease in Poland. Eur. J. Clin. Microbiol. Infect. Dis. 34: 779–787.10.1007/s10096-014-2283-825475124
]Search in Google Scholar
[
World Health Organisation (WHO). 2005. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech. Rep. Ser. 927 (Annex 2): 64–98.
]Search in Google Scholar
[
Wernette C.M., C.E. Frasch, D. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S.A. Quataert, S. Hildreth, D.J. Sikkema and others. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10: 514–519.10.1128/CDLI.10.4.514-519.2003
]Search in Google Scholar
[
Wysocki J., J. Brzostek, H. Szymański,B. Tetiurka, E. Toporowska-Kowalska, K. Wasowska-Królikowska, D.A. Sarkozy, P.C. Giardina, W.C. Gruber and others. 2015. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine administered to older infants and children naïve to pneumococcal vaccination. Vaccine 33: 1719–1725.10.1016/j.vaccine.2015.02.00525698485
]Search in Google Scholar
